source scope and renal guidanceNew v6.8
Before use: Migalastat oral capsules (Galafold)
Use indexed eGFR and the qualifying genetic indication; this is not a daily or pediatric regimen.
What to reconcileConfirm exact indication, indexed renal estimate and alternate-day schedule; use the newer primary label for full prescribing context.
2 source identities and dates
Migalastat oral capsules (Galafold) - selected label sectionsDailyMed / GALAFOLD US labeling | Source revision: 03/2025
US GALAFOLD 123 mg oral capsules for adults with Fabry disease and a qualifying amenable GLA variant; do not extrapolate to pediatric patients.
Read this stored source Migalastat oral capsules (Galafold) - RX mirror renal summaryGlobalRPh RX List / product-label mirror | Source revision: 06/2024
US GALAFOLD 123 mg oral capsules for adults with Fabry disease and a qualifying amenable GLA variant; do not extrapolate to pediatric patients.
Read this stored source Selected source reconciliation only; independent clinician adjudication pending. Added: v6.8.
source ambiguity
The printed renal bands overlap at exactly 50
The selected source uses an indexed creatinine-clearance unit and overlapping renal ranges.
What to reconcileDo not silently convert units or choose an unsupported boundary. Confirm the current product label and clarify the exact threshold.
1 source identities and dates
GlobalRPh RX List - ZavescaGlobalRPh-hosted RX List | Source revision: Revision date not established in selected retrieval.
Adult type 1 Gaucher disease; not a miglustat combination regimen for a different disease.
Read this stored source Source difference identified; final patient-specific adjudication required. Added: vearlier.
ambiguous threshold
Exactly 50 occurs in two printed renal bands
The source assigns different starting frequencies to ranges that share 50 as a boundary, and prints clearance normalized to 1.73 m2.
What to reconcileConfirm the exact product label and boundary interpretation before prescribing. The tool does not resolve this by rounding, averaging or converting an indexed measure silently.
1 source identities and dates
GlobalRPh RX List - ZAVESCAGlobalRPh-hosted RX List | Source revision: November 2017
Adult ZAVESCA for mild/moderate type 1 Gaucher disease when enzyme replacement is not an option.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.7.
formulation scope
OPFOLDA: paired therapy and every-other-week renal dosing
The OPFOLDA instruction belongs to a weight-based regimen paired with POMBILITI, not a daily Gaucher-disease miglustat schedule.
What to reconcileConfirm paired therapy, body weight, renal method and infusion timing. Do not transfer a ZAVESCA regimen.
1 source identities and dates
GlobalRPh RX List - OPFOLDAGlobalRPh-hosted RX List | Source revision: RX page prints July 2024.
Miglustat - OPFOLDA with POMBILITI; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
institutional regimen
IV label daily ceiling versus institutional loading and high-dose practice
The MINOCIN IV label sets a renal-impairment ceiling of 200 mg per 24 hours. UCSF lists a 200-mg loading dose followed by 100 mg every 12 hours without renal adjustment, and selected higher-dose treatment with specialist input. Initial-day exposure or high-dose maintenance can exceed the label ceiling.
What to reconcileThis is a real exposure difference, not just alternate wording. Obtain infectious-disease/antimicrobial-stewardship input and document the exact IV product, indication, renal status, total first-day exposure and monitoring before choosing an approach. Do not silently merge the label cap with an institutional schedule.
2 source identities and dates
Minocycline - MINOCIN IV renal labelDailyMed / NLM; manufacturer prescribing information | Source revision: Prescribing text revised March 2025
Adult MINOCIN intravenous formulation; not acne extended-release tablets or capsules.
Read this stored source UCSF - systemic minocycline institutional strategyUCSF Infectious Diseases Management Program | Source revision: Revision date not stated in the reviewed page.
Adults; systemic immediate-release oral or IV minocycline institutional regimen.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.4.
guideline difference
Minocycline injection: label ceiling versus institutional dosing
The injection label limits total daily dosing in renal impairment. UCSF describes a loading dose and selected higher-dose practice without a renal reduction. A loading day or high-dose regimen is not silently reconciled with that ceiling.
What to reconcileKeep the label and institutional pathways separate; obtain stewardship adjudication and retain BUN, creatinine and magnesium-vehicle monitoring.
2 source identities and dates
GlobalRPh RX List - MINOCIN injectionGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Minocycline - MINOCIN injection; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Minocycline - UCSF antimicrobial guidanceUniversity of California San Francisco, Infectious Diseases Management Program | Source revision: Source revision date not established in selected retrieval.
Minocycline - UCSF antimicrobial guidance; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
evidence limit
PYRUKYND: limited PK data are not a dosing algorithm
Only the stated higher-function band has the cited exposure comparison; lower-function data are limited or absent.
What to reconcileDisplay the evidence gap rather than a broad no-adjustment conclusion.
1 source identities and dates
GlobalRPh RX List - PYRUKYNDGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Mitapivat - PYRUKYND tablets; selected renal passages, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.0.
retrieval gap and route
DailyMed recovered renal guidance; the RX page remains incomplete
The fetched RX rendering stopped before usable renal instructions. A separate exact JELMYTO DailyMed summary now supplies the renal restriction and obstruction precautions.
What to reconcileUse the labeled pyelocalyceal formulation, not IV mitomycin or another urinary formulation. An alternative-label import does not convert the truncated RX page into a successful RX renal review.
1 source identities and dates
Mitomycin pyelocalyceal solution (JELMYTO)DailyMed / UroGen Pharma, Inc. | Source revision: June 2025
Adult JELMYTO, pyelocalyceal instillation only; exact UroGen label.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.6.
population scope
MYDAYIS: adult and adolescent severe-renal ceilings differ
The adolescent severe-impairment instruction is more restrictive than the adult ceiling. The ESRD restriction is separate.
What to reconcileConfirm age, exact product and indexed renal measure; do not use the adult maximum for an adolescent.
1 source identities and dates
GlobalRPh RX List - MYDAYISGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Mixed amphetamine salts - MYDAYIS; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
source scope and renal guidance
Before use: Molnupiravir - LAGEVRIO capsules
UCSF prints >50 and <50, omitting exactly 50; the EUA renal instruction is not limited to those headings.
What to reconcileConfirm the exact product, indication, renal measure and full source before prescribing.
3 source identities and dates
GlobalRPh RX List - LagevrioGlobalRPh-hosted RX List | Source revision: Revision not established in selected RX sections
Adult COVID-19 EUA population; not FDA-approved labeling for unrestricted indications.
Read this stored source Molnupiravir - LAGEVRIO capsulesDailyMed / NLM exact product labeling | Source revision: 6/2024 EUA fact sheet
Adult COVID-19 EUA population; not FDA-approved labeling for unrestricted indications.
Read this stored source Molnupiravir - UCSF adult renal guidanceUCSF Infectious Diseases Management Program | Source revision: Revision not established in selected retrieval
Adult institutional renal reference; eligibility and duration require the separate EUA source.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.
evidence limit
OJJAARA: low-eGFR PK observations do not establish dialysis dosing
The studied lower renal boundary is unusual; ESRD requiring dialysis remains unknown.
What to reconcilePreserve the actual population boundary and avoid creating a dialysis regimen.
1 source identities and dates
GlobalRPh RX List - OJJAARAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Momelotinib - OJJAARA tablets; selected source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.9.
pk prediction not validation
A prediction about severe impairment is not observed evidence
The mirror predicts little severe-renal effect but explicitly states that it was not evaluated.
What to reconcileKeep this classified as PK-only; do not translate an expectation into a proven no-adjustment or dialysis regimen.
1 source identities and dates
GlobalRPh RX List - APHEXDAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v5.5.
population scope
MYHIBBIN: kidney-transplant dose ceiling is not every transplant setting
The selected severe-impairment ceiling is stated for kidney-transplant recipients. Mycophenolic-acid products have separate formulations and evidence.
What to reconcilePreserve transplant organ, formulation and monitoring context; do not declare all mycophenolate products interchangeable.
1 source identities and dates
GlobalRPh RX List - MYHIBBINGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Mycophenolate mofetil - MYHIBBIN oral suspension; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
evidence limit
MYFORTIC: pharmacokinetics are not a universal renal dose
The renal discussion draws on mycophenolate-mofetil data and metabolite exposure; it does not supply a universal renal dose or interchangeable product ceiling.
What to reconcileUse the complete transplant-specific regimen and monitoring rather than inferring a no-adjustment protocol from this PK supplement.
1 source identities and dates
GlobalRPh RX List - MYFORTICGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Mycophenolic acid - MYFORTIC delayed release; selected renal source sections only, not a complete prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.
boundary units
CORGARD: indexed clearance and interval ranges
The table prints BSA-indexed CrCl and interval ranges. Replacing these with unindexed clearance or a midpoint changes the source instructions.
What to reconcileRetain the printed units and bands; resolve fractional boundary gaps without inventing an interval.
1 source identities and dates
GlobalRPh RX List - CORGARDGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Nadolol - CORGARD tablets; selected source sections, not a full prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.
evidence limit
SYMPROIC: renal pharmacokinetics are not a class-wide regimen
Similar single-dose exposure and lack of dialysis removal do not establish renal instructions for other opioid antagonists.
What to reconcileKeep the adult indication, product, interaction review and PK-study scope attached to this card.
1 source identities and dates
GlobalRPh RX List - SYMPROICGlobalRPh-hosted RX List | Source revision: RX page prints July 2021.
Naldemedine - SYMPROIC tablets; selected source sections, not a full prescribing monograph.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.